PDCD1 and neoplasm: Interestingly, durable tumour responses have been observed after early discontinuation (< 2 years) of PD-1 blockade [14–16], not only in patients who achieved a complete response (CR) [16] but also in patients with a partial response (PR) or stable disease (SD) [17, 18].